Meningococcal Vaccines Forecast
Datamonitor Healthcare forecasts meningococcal sales in the US and the public sector of the five major EU markets (France, Germany, Italy, Spain, and the UK) to rise from $1.2bn in 2017 to $1.7bn in 2026, at a compound annual growth rate (CAGR) of 3.7%. The primary growth drivers will be the increasing uptake of meningococcal B vaccines and the anticipated launch of a pipeline pentavalent vaccine.
Read more...